Please login to the form below

Not currently logged in

Amryt Pharma appoints Jordi Casals as head of Europe

He joins the company from Aegerion Pharmaceuticals

Jordi CasalsAmryt Pharma, a company focused on treatments for rare and orphan diseases, has appointed Jordi Casals as the biopharma’s head of Europe.

Taking responsibility for leading and developing Amryt’s European operations, Casals’ new role will see him initially focus on the sales growth of the company’s commercial asset Lojuxta - a treatment for adult patients with Homozygous Familial Hypercholesterolaemia.

Dr Joe Wiley, chief executive officer of Amryt, said: “I am pleased to welcome Jordi to our senior management team as the company’s head of Europe.

“His significant commercial experience of European markets will help us to drive and further develop Amryt’s growth across this key region.”

Casal has over 20 years’ experience in the pharmaceutical and biotech industry and most recently worked for Aegerion Pharmaceuticals as a consultant, managing its commercial operations in the Iberia region.

Prior to this, he worked for eight years at Alexion Pharmaceuticals, latterly as vice president commercial operations, Western Europe.

9th March 2018

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...
When is it time to rebrand?